Beacons Pharmaceuticals and Health Products, the largest generic pharmaceutical company in Singapore, will soon enter the Indian market.
However, the three decade old and the oldest Singapore pharmaceutical company's entry into India is not aimed to take on the might of Indian generic companies, but to help domestic pharma companies set up turnkey pharmaceutical projects in India.
Beacons has partnered with the Pune based pharmaceutical consultancy and business development firm ONCO Life Sciences Pvt.Ltd to market its new Satellite Process Assurance Hub (SPAH) engineering solution in India, targeting the 100 odd US FDA approved plants and new projects coming up in India.
SPAH is a new patent pending engineering solution developed by Beacon, which is now in talks with a few European pharma majors to implement the SPAH.
According to Onco sources, SPAH design based plants will have many advantages when compared to conventional designs like monitoring production processes for safety, compliance, quality, non-intrusive maintenance of through-the-wall process equipment, non-intrusive visitor viewing, more efficient and ergonomic operations, better and cost effective monitoring of people and material flow, facilitate cost, compliance and performance of technology transfer from process lab to production etc.
Its features include control hub overlooking production suites, tech corridor wrap around production suites along perimeter of plant, viewing gallery, uni-directional U-shaped layout of production suites according to process flow, QC labs in close proximity to production suites, cost effective security hub at the entrance monitoring both material and people flow, R&D pilot lab well embedded and integrated with the production facility in single building etc.
Beacon, which manufacturers over 200 formulations, is also into contract manufacturing, repackaging and other allied support services for the pharmaceutical industry, and has clients in China, Thailand and the Far East.